Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes

Nakonechny, Quentin; Gilks, C. Blake

doi:10.1016/j.path.2016.01.003

Cited by 25 publications

(17 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7,8 Family history (primarily patients having ≥2 firstdegree relatives with ovarian cancer)-including linkage with BRCA1 and BRCA2 genotypes (hereditary breast and ovarian cancer syndrome) or families affected by Lynch syndrome (hereditary nonpolyposis colorectal cancer syndrome)-is associated with earlyonset disease. [9][10][11][12][13][14][15][16][17][18][19][20][21] Lynch syndrome is associated with risk for endometrioid carcinomas, clear cell carcinomas, and papillary serous carcinomas. [9][10][11] In women at high risk (with either BRCA1 or BRCA2 mutations), prophylactic bilateral salpingooophorectomy (BSO) is associated with a reduced risk for breast, ovarian, fallopian tube, and primary peritoneal cancers.…”

Section: Epidemiologymentioning

confidence: 99%

“…[9][10][11][12][13][14][15][16][17][18][19][20][21] Lynch syndrome is associated with risk for endometrioid carcinomas, clear cell carcinomas, and papillary serous carcinomas. [9][10][11] In women at high risk (with either BRCA1 or BRCA2 mutations), prophylactic bilateral salpingooophorectomy (BSO) is associated with a reduced risk for breast, ovarian, fallopian tube, and primary peritoneal cancers. [22][23][24][25][26][27] Occult ovarian cancer is sometimes found after prophylactic salpingooophorectomy, thus emphasizing the need for careful pathologic review of the ovaries and tubes (see "Risk-Reducing SalpingoOophorectomy [RRSO] Protocol" in the complete version of these guidelines, available at NCCN.org [OV-A]).…”

Section: Epidemiologymentioning

confidence: 99%

“…Lynch syndrome is associated with risk for clear cell carcinomas, endometrioid carcinomas, and papillary serous carcinomas. [9][10][11] For patients with stage IA to IC disease, recommended postoperative treatment is either intravenous paclitaxel/carboplatin or docetaxel/carboplatin. 143 Fertility-sparing surgery and/or observation/monitoring are options for patients with unilateral clear cell borderline tumors (see LCOH-6; page 1141).…”

Section: Clear Cell Carcinomamentioning

confidence: 99%

“…141 Lynch syndrome is associated with risk for endometrioid carcinomas, clear cell carcinomas, and serous carcinomas. [9][10][11] Patients with grade 1 (low-grade) serous carcinomas may present with more advanced disease, but they often have more indolent disease and present at a younger age than those with high-grade serous carci-nomas. 88,151 Serous carcinomas are usually positive for WT1 and estrogen receptors.…”

Section: Grade 1 (Low-grade) Serous/endometrioid Epithelial Carcinomasmentioning

confidence: 99%

See 3 more Smart Citations

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Morgan

Armstrong

Alvarez

et al. 2016

J Natl Compr Canc Netw

307

233

View full text Add to dashboard Cite

Section: Epidemiologymentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

Section: Clear Cell Carcinomamentioning

confidence: 99%

Section: Grade 1 (Low-grade) Serous/endometrioid Epithelial Carcinomasmentioning

confidence: 99%

See 2 more Smart Citations

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Morgan

Armstrong

Alvarez

et al. 2016

J Natl Compr Canc Netw

307

233

View full text Add to dashboard Cite

“…The histotypes of ovarian carcinoma form the basis for assessment of risk of hereditary cancer syndromes; patients diagnosed with HGSC have an approximately 20% likelihood of an inherited BRCA1 or BRCA2 mutation, while those with EC or CCC have a risk of Lynch syndrome identical to that of patients presenting with endometrial or colorectal carcinoma . To not screen patients presenting with HGSC for germline BRCA1 and BRCA2 mutations denies their female relatives, who may be mutation carriers, the possibility of highly effective risk‐reducing surgery.…”

Section: Ovary and Fallopian Tubementioning

confidence: 99%

The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century

Singh

Gilks

2016

Histopathology

View full text Add to dashboard Cite

The era of molecular medicine has led to dramatically improved understanding of the genetic events that give rise to different types of cancers. In the case of gynaecological malignancies, this has resulted in distinct shifts in how these tumours are diagnosed in routine surgical pathology practice, with an increased emphasis on accurate subtype diagnosis. This has happened across all sites in the gynaecological tract and for most cell types, but in ways that are site-specific and may appear to be subtle, as in most instances the diagnostic terminology has not changed. For example, the diagnosis of clear cell carcinoma of the ovary is still in use, but the diagnostic criteria and clinical implications are different in 2017 from what they were in 2000. As a result, there can be a failure to appreciate how important these changes are and the resulting necessity of incorporating them into our daily practice. In this review we will describe changes in diagnostic surgical pathology occasioned by improved understanding of molecular events during pathogenesis, for cancers of ovary/tube, endometrium, cervix and vulva, and highlight how current practice differs from that of only a few years ago.

show abstract

Pediatric, adolescent, and young adult breast and reproductive tumors

Harris

Rowell

Jayasinghe

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Tumors of the breast and reproductive organs that occur in children, adolescents, and young adults (AYA) have different biological features and can present special challenges. Although prognosis for these tumors is generally favorable, the long‐term effects of treatment can be debilitating. Treatments are often multimodal and may include surgery as well as chemotherapy and/or radiation, which can cause considerable distress and anxiety related to loss of femininity or masculinity, concern over future fertility, or sexual dysfunction. Thus, tumors of the reproductive organs in pediatric/AYA patients require special consideration of the treatment effects beyond the intended oncologic outcome. Multidisciplinary teams should be involved in their care and address issues of fertility, sexual dysfunction, and psychosexual concerns before treatment begins. This review addresses histology, risk factors, prognosis, staging and treatment of gynecologic, breast and testicular cancers in pediatric and AYA patients.

show abstract

Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes

Cited by 25 publications

References 74 publications

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century

Pediatric, adolescent, and young adult breast and reproductive tumors

Contact Info

Product

Resources

About